Effects of nevirapine and efavirenz on human adipocyte differentiation, gene expression, and release of adipokines and cytokines

Antiviral Research

Volumn 91, Issue 2, 2011, Pages 112-119

  Díaz Delfín, Julieta ^a   del Mar Gutierrez M ^b   Gallego Escuredo, José M ^a   Domingo, Joan C ^a   Gracia Mateo, M ^b   Villarroya, Francesc ^a   Domingo, Pere ^b   Giralt, Marta ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Adipocyte; Adipokine; Efavirenz; Lipodystrophy; Nevirapine; Non nucleoside analog reverse transcriptase inhibitor

Indexed keywords

ANTIRETROVIRUS AGENT; COMPLEMENTARY DNA; EFAVIRENZ; MESSENGER RNA; MITOCHONDRIAL DNA; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA;

ADIPOCYTE; ADIPOGENESIS; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; CYTOKINE RELEASE; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG EFFECT; ENZYME ACTIVITY; GENE EXPRESSION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LIPODYSTROPHY; PRIORITY JOURNAL; PROADIPOCYTE;

ADIPOCYTES; ADIPOGENESIS; ADIPOKINES; ANTI-RETROVIRAL AGENTS; BENZOXAZINES; CCAAT-ENHANCER-BINDING PROTEIN-ALPHA; CELL SURVIVAL; CELLS, CULTURED; CYTOKINES; DOWN-REGULATION; GENE EXPRESSION; HEPATOCYTE GROWTH FACTOR; HUMANS; LACTIC ACID; MICROBIAL SENSITIVITY TESTS; NEVIRAPINE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PPAR GAMMA; RNA-DIRECTED DNA POLYMERASE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 79958272982     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2011.04.018     Document Type: Article

References (41)

1. Bell L.N., Cai L., Johnstone B.H., Traktuev D.O., March K.L., Considine R.V. A central role for hepatocyte growth factor in adipose tissue angiogenesis. Am. J. Physiol. Endocrinol. Metab. 2008, 294:E336-E344.
2. Caron M., Auclair M., Kornprobst M., Lagathu C., Capeau J. Nevirapine did not alter cell differentiation, lipid metabolism, insulin response and survival in cultured adipocytes. Antivir. Ther. 2004, 9:L27.
3. Colebunders R., Kamya M.R., Laurence J., Kambugu A., Byakwaga H., Mwebaze P.S., Muganga A.M., Katwere M., Katabira E. First-line antiretroviral therapy in Africa - how evidence-base are our recommendations?. AIDS Rev. 2005, 7:148-154.
4. Cooper C.L., van Heeswijk R.P. Once-daily nevirapine dosing: a pharmacokinetics, efficacy and safety review. HIV Med. 2007, 8:1-7.
5. de Béthune M.P. Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989-2009). Antiviral Res. 2010, 85:75-90.
6. Domingo P., Matías-Guiu X., Pujol R.M., Domingo J.C., Arroyo J.A., Sambeat M.A., Vázquez G. Switching to nevirapine decreases insulin levels but does not improve subcutaneous adipocyte apoptosis in patients with highly active antiretroviral therapy-associated lipodystrophy. J. Infect. Dis. 2001, 184:1197-1201.
7. Dupin N., Buffet M., Marcelin A.G., Lamotte C., Gorin I., Ait-Arkoub Z., Tréluyer J.M., Bui P., Calvez V., Peytavin G. HIV and antiretroviral drug distribution in plasma and fat tissue of HIV-infected patients with lipodystrophy. AIDS 2002, 16:2419-2424.
8. El Hadri K., Glorian M., Monsempes C., Dieudonné M.N., Pecquery R., Giudicelli Y., Andreani M., Dugail I., Fève B. In vitro suppression of the lipogenic pathway by the nonnucleoside reverse transcriptase inhibitor efavirenz in 3T3 and human preadipocytes or adipocytes. J. Biol. Chem. 2004, 279:15130-15141.
9. Esposito V., Manente L., Perna A., Gargiulo M., Viglietti R., Sangiovanni V., Doula N., Liuzzi G., Baldi A., De Luca A., Chirianni A. Role of NEDD8 in HIV-associated lipodystrophy. Differentiation 2009, 77:148-153.
10. Fisac C., Fumero E., Crespo M., Roson B., Ferrer E., Virgili N., Ribera E., Gatell J.M., Podzamczer D. Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine. AIDS 2005, 19:917-925.
11. Gallego-Escuredo J.M., Del Mar Gutierrez M., Diaz-Delfin J., Domingo J.C., Mateo M.G., Domingo P., Giralt M., Villarroya F. Differential effects of efavirenz and lopinavir/ritonavir on human adipocyte differentiation, gene expression and release of adipokines and pro-inflammatory cytokines. Curr. HIV Res. 2010, 8:545-553.
12. Gazzard B.G., Anderson J., Babiker A., Boffito M., Brook G., Brough G., Churchill D., Cromarty B., Das S., Fisher M., Freedman A., Geretti A.M., Johnson M., Khoo S., Leen C., Nair D., Peters B., Phillips A., Pillay D., Pozniak A., Walsh J., Wilkins E., Williams I., Williams M., Youle M., Treatment Guidelines Writing Group B.H.I.V.A. British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med. 2008, 9:563-608.
13. Gonzalez-Tome M.I., Amador J.T., Peña M.J., Gomez M.L., Conejo P.R., Fontelos P.M. Outcome of protease inhibitor substitution with nevirapine in HIV-1 infected children. BMC Infect. Dis. 2008, 8:144.
14. Hammer S.M., Eron J.J., Reiss P., Schooley R.T., Thompson M.A., Walmsley S., Cahn P., Fischl M.A., Gatell J.M., Hirsch M.S., Jacobsen D.M., Montaner J.S., Richman D.D., Yeni P.G., Volberding P.A. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008, 300:555-570.
15. Haubrich R.H., Riddler S.A., DiRienzo A.G., Komarow L., Powderly W.G., Klingman K., Garren K.W., Butcher D.L., Rooney J.F., Haas D.W., Mellors J.W., Havlir D.V. Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS 2009, 23:1109-1118. AIDS Clinical Trials Group (ACTG) A5142 Study Team.
16. Hauner H. Secretory factors from human adipose tissue and their functional role. Proc. Nutr. Soc. 2005, 64:163-169.
17. Kadowaki T., Yamauchi T., Kubota N., Hara K., Ueki K., Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J. Clin. Invest. 2006, 116:1784-1792.
18. Kim J.H., Bachmann R.A., Chen J. Interleukin-6 and insulin resistance. Vitam. Horm. 2009, 80:613-633.
19. Landriscina M., Modoni S., Fabiano A., Fersini A., Barone C., Ambrosi A., Cignarelli M. Cell differentiation and iodine-131 uptake in poorly differentiated thyroid tumour in response to nevirapine. Lancet Oncol. 2006, 7:877-879.
20. Landriscina M., Altamura S.A., Roca L., Gigante M., Piscazzi A., Cavalcanti E., Costantino E., Barone C., Cignarelli M., Gesualdo L., Ranieri E. Reverse transcriptase inhibitors induce cell differentiation and enhance the immunogenic phenotype in human renal clear-cell carcinoma. Int. J. Cancer 2008, 122:2842-2850.
21. Landriscina M., Bagalà C., Piscazzi A., Schinzari G., Quirino M., Fabiano A., Bianchetti S., Cassano A., Sica G., Barone C. Nevirapine restores androgen signaling in hormone-refractory human prostate carcinoma cells both in vitro and in vivo. Prostate 2009, 690:744-754.
22. Laughton C. Measurement of the specific lipid content of attached cells in microtiter cultures. Anal. Biochem. 1986, 156:307-314.
23. Mangiacasale R., Pittoggi C., Sciamanna I., Careddu A., Mattei E., Lorenzini R., Travaglini L., Landriscina M., Barone C., Nervi C., Lavia P., Spadafora C. Exposure of normal and transformed cells to nevirapine, a reverse transcriptase inhibitor, reduces cell growth and promotes differentiation. Oncogene 2003, 22:2750-2761.
24. Modoni S., Landriscina M., Fabiano A., Fersini A., Urbano N., Ambrosi A., Cignarelli M. Reinduction of cell differentiation and 131I uptake in a poorly differentiated thyroid tumor in response to the reverse transcriptase (RT) inhibitor nevirapine. Cancer Biother. Radiopharm. 2007, 22:289-295.
25. Negredo E., Paredes R., Bonjoch A., Tuldrà A., Fumaz C.R., Gel S., Garcés B., Johnston S., Arnó A., Balagué M., Jou A., Tural C., Sirera G., Romeu J., Cruz L., Francia E., Domingo P., Arrizabalaga J., Ruiz I., Arribas J.R., Ruiz L., Clotet B. Benefit of switching from a protease inhibitor (PI) to nevirapine in PI-experienced patients suffering acquired HIV-related lipodystrophy syndrome (AHL): interim analysis at 3 months of follow-up. Antivir. Ther. 1999, 3:23-28.
26. Petit J.M., Duong M., Masson D., Buisson M., Duvillard L., Bour J.B., Brindisi M.C., Galland F., Guiguet M., Gambert P., Portier H., Vergès B. Serum adiponectin and metabolic parameters in HIV-1-infected patients after substitution of nevirapine for protease inhibitors. Eur. J. Clin. Invest. 2004, 34:569-575.
27. Riddler S.A., Haubrich R., DiRienzo A.G., Peeples L., Powderly W.G., Klingman K.L., Garren K.W., George T., Rooney J.F., Brizz B., Lalloo U.G., Murphy R.L., Swindells S., Havlir D., Mellors J.W. Class-sparing regimens for initial treatment of HIV-1 infection. N. Engl. J. Med. 2008, 358:2095-2106. AIDS Clinical Trials Group Study A5142 Team.
28. Rodríguez de la Concepción M.L., Yubero P., Domingo J.C., Iglesias R., Domingo P., Villarroya F., Giralt M. Reverse transcriptase inhibitors alter uncoupling protein-1 and mitochondrial biogenesis in brown adipocytes. Antivir. Ther. 2005, 10:515-526.
29. Schlüter A., Yubero P., Iglesias R., Giralt M., Villarroya F. The chlorophyll-derived metabolite phytanic acid induces white adipocyte differentiation. Int. J. Obes. Relat. Metab. Disord. 2002, 26:1277-1280.
30. Sciamanna I., Landriscina M., Pittoggi C., Quirino M., Mearelli C., Beraldi R., Mattei E., Serafino A., Cassano A., Sinibaldi-Vallebona P., Garaci E., Barone C., Spadafora C. Inhibition of endogenous reverse transcriptase antagonizes human tumor growth. Oncogene 2005, 24:3923-3931.
31. Spadafora C. Endogenous reverse transcriptase: a mediator of cell proliferation and differentiation. Cytogenet. Genome Res. 2004, 105:346-350.
32. Staszewski S., Morales-Ramirez J., Tashima K.T., Rachlis A., Skiest D., Stanford J., Stryker R., Johnson P., Labriola D.F., Farina D., Manion D.J., Ruiz N.M. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N. Engl. J. Med. 1999, 341:1865-1873.
33. Stefanidis K., Loutradis D., Vassiliou L.V., Anastasiadou V., Kiapekou E., Nikas V., Patris G., Vlachos G., Rodolakis A., Antsaklis A. Nevirapine induces growth arrest and premature senescence in human cervical carcinoma cells. Gynecol. Oncol. 2008, 111:344-349.
34. Tong Q., Sankal J.L., Hadigan C.M., Tan G., Rosenberg E.S., Kanki P.J., Grinspoon S.K., Hotamisligil G.S. Regulation of adiponectin in human immunodeficiency virus-infected patients: relationship to body composition and metabolic indices. J. Clin. Endocrinol. Metab. 2003, 88:1559-1564.
35. van Leth F., Phanuphak P., Ruxrungtham K., Baraldi E., Miller S., Gazzard B., Cahn P., Lalloo U.G., van der Westhuizen I.P., Malan D.R., Johnson M.A., Santos B.R., Mulcahy F., Wood R., Levi G.C., Reboredo G., Squires K., Cassetti I., Petit D., Raffi F., Katlama C., Murphy R.L., Horban A., Dam J.P., Hassink E., van Leeuwen R., Robinson P., Wit F.W., Lange J.M. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 2004, 363:1253-1263. 2NN Study team.
36. van Leth F., Phanuphak P., Stroes E., Gazzard B., Cahn P., Raffi F., Wood R., Bloch M., Katlama C., Kastelein J.J., Schechter M., Murphy R.L., Horban A., Hall D.B., Lange J.M., Reiss P. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. PLoS Med. 2004, 1:e19.
37. Vernochet C., Azoulay S., Duval D., Guedj R., Cottrez F., Vidal H., Ailhaud G., Dani C. Human immunodeficiency virus protease inhibitors accumulate intocultured human adipocytes and alter expression of adipocytokines. J. Biol. Chem. 2005, 280:2238-2243.
38. Villarroya F., Domingo P., Giralt M. Lipodystrophy associated with highly active anti-retroviral therapy for HIV infection: the adipocyte as a target of anti-retroviral-induced mitochondrial toxicity. Trends Pharmacol. Sci. 2005, 26:88-93.
39. Villarroya F., Domingo P., Giralt M. Lipodystrophy in HIV 1-infected patients: lessons for obesity research. Int. J. Obes. (Lond.) 2007, 31:1763-1776.
40. Villarroya F., Domingo P., Giralt M. Mechanisms of antiretroviral-induced mitochondrial dysfunction in adipocytes and adipose tissue: in-vitro, animal and human adipose tissue studies. Curr. Opin. HIV AIDS 2007, 2:261-267.
41. Zhou J., Paton N.I., Ditangco R., Chen Y.M., Kamarulzaman A., Kumarasamy N., Lee C.K., Li P.C., Merati T.P., Phanuphak P., Pujari S., Vibhagool A., Zhang F., Chuah J., Frost K.R., Cooper D.A., Law M.G. Experience with the use of a first-line regimen of stavudine, lamivudine and nevirapine in patients in the TREAT Asia HIV Observational Database. HIV Med. 2007, 8:8-16.